Early detection of cognitive dysfunction in patients with multiple sclerosis: Implications on outcome

被引:3
|
作者
Naseer, Maged Abdel [1 ]
Fathi, Shereen [1 ]
Labib, Dalia M. [1 ]
Khalil, Dalia H. [2 ]
Aboulfotooh, Alshaimaa M. [1 ]
Magdy, Rehab [1 ]
机构
[1] Cairo Univ, Dept Neurol, Fac Med, Cairo, Egypt
[2] Cairo Univ, Dept Ophthalmol, Fac Med, Cairo, Egypt
关键词
Multiple sclerosis; secondary progressive phase; cognitive impairment; optical coherence tomography; MEMORY IMPAIRMENT; PERFORMANCE; BRAIN;
D O I
10.1017/BrImp.2019.26
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Cognitive impairment in multiple sclerosis (MS) has a complex relationship with disease progression and neurodegeneration. The aim of this study was to shed light on the importance of early detection of cognitive impairment in MS patients. Methods: The study comprised two groups of definite MS patients, relapsing remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS), each with 25 patients. Physical disability was assessed using the Expanded Disability Status Scale (EDSS), while the risk of secondary progression was assessed using the Bayesian Risk Estimate for Multiple Sclerosis (BREMS). Cognitive functions were assessed using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) and Controlled Oral Word Association Test (COWAT). Assessment of neurodegeneration was done using optical coherence tomography (OCT) via quantification of retinal nerve fiber layer (RNFL). Results: MS patients with higher RNFL thickness demonstrated a larger learning effect size than patients who had lower values in RNFL thickness regardless of MS type. RRMS patients showed significant improvement in delayed recall after giving cues than SPMS. The symbol digit modalities test was the only neuropsychological test that showed a significant negative correlation with EDSS (P= 0.009). There was a statistically significant negative correlation between BREMS scores and performance in all neuropsychological tests. Conclusion: Inclusion of neurocognitive evaluation in the periodic assessment of MS patients is mandatory to detect patients at increased risk of secondary progression. The thickness of RNFL is suggested as a method to estimate the expected benefit of cognitive rehabilitation, regardless of MS type.
引用
收藏
页码:208 / 216
页数:9
相关论文
共 50 条
  • [1] Cognitive dysfunction in early multiple sclerosis: a review
    McNicholas, N.
    O'Connell, K.
    Yap, S. M.
    Killeen, R. P.
    Hutchinson, M.
    McGuigan, C.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2018, 111 (06) : 359 - 364
  • [2] MRI predictors of cognitive outcome in early multiple sclerosis
    Deloire, M. S. A.
    Ruet, A.
    Hamel, D.
    Bonnet, M.
    Dousset, V.
    Brochet, B.
    NEUROLOGY, 2011, 76 (13) : 1161 - 1167
  • [3] Montreal Cognitive Assessment (MoCA) in the detection of cognitive dysfunction in multiple sclerosis
    Santana, M. I. J.
    Batista, S.
    Afonso, A. C.
    Simoes, M. R.
    Sousa, L.
    Cunha, L.
    Freitas, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 622 - 622
  • [4] How to detect cognitive dysfunction at early stages of multiple sclerosis?
    Deloire, M. S. A.
    Bonnet, M. C.
    Salort, E.
    Arimone, Y.
    Boudineau, M.
    Petry, K. G.
    Brochet, B.
    MULTIPLE SCLEROSIS JOURNAL, 2006, 12 (04) : 445 - 452
  • [5] Evaluation of the determinants of cognitive dysfunction in patients with multiple sclerosis
    Alireza Haji Seyed Javadi
    Ali Akbar Shafikhani
    Neda Beizapour
    Middle East Current Psychiatry, 29
  • [6] Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis
    Shumita Roy
    Ralph H. B. Benedict
    Allison S. Drake
    Bianca Weinstock-Guttman
    CNS Drugs, 2016, 30 : 209 - 225
  • [7] Treatment and management of cognitive dysfunction in patients with multiple sclerosis
    DeLuca, John
    Chiaravalloti, Nancy D.
    Sandroff, Brian M.
    NATURE REVIEWS NEUROLOGY, 2020, 16 (06) : 319 - 332
  • [8] Evaluation of the determinants of cognitive dysfunction in patients with multiple sclerosis
    Javadi, Alireza Haji Seyed
    Shafikhani, Ali Akbar
    Beizapour, Neda
    MIDDLE EAST CURRENT PSYCHIATRY-MECPSYCH, 2022, 29 (01):
  • [9] Treatment and management of cognitive dysfunction in patients with multiple sclerosis
    John DeLuca
    Nancy D. Chiaravalloti
    Brian M. Sandroff
    Nature Reviews Neurology, 2020, 16 : 319 - 332
  • [10] Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis
    Roy, Shumita
    Benedict, Ralph H. B.
    Drake, Allison S.
    Weinstock-Guttman, Bianca
    CNS DRUGS, 2016, 30 (03) : 209 - 225